Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $473.8 million.

  • Pharming's Liabilities and Shareholders Equity rose 1134.42% to $473.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 130.32%. This contributed to the annual value of $400.0 million for FY2024, which is 1358.29% down from last year.
  • Per Pharming's latest filing, its Liabilities and Shareholders Equity stood at $473.8 million for Q3 2025, which was up 1134.42% from $446.3 million recorded in Q2 2025.
  • Pharming's Liabilities and Shareholders Equity's 5-year high stood at $420.4 billion during Q1 2021, with a 5-year trough of $401021.4 in Q4 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $425.5 million (2024), whereas its average is $42.6 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 9999.99% in 2021, then soared by 10607813.42% in 2022.
  • Pharming's Liabilities and Shareholders Equity (Quarter) stood at $401021.4 in 2021, then skyrocketed by 106078.13% to $425.8 million in 2022, then rose by 8.7% to $462.9 million in 2023, then dropped by 13.58% to $400.0 million in 2024, then rose by 18.45% to $473.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $473.8 million for Q3 2025, versus $446.3 million for Q2 2025 and $403.2 million for Q1 2025.